| ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ and Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients (Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.). Neoplasma. Bratislava: Slovenská akademie vied, 2018, vol. 65, No 4, p. 585-591. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2018_170519N363. |
Other formats:
BibTeX
LaTeX
RIS
@article{1404546,
author = {Štork, Martin and Ševčíková, Sabina and Adam, Zdeněk and Krejčí, Marta and Sandecká, Viera and Král, Zdeněk and Brožová, Lucie and Velichová, Roberta and Pour, Luděk},
article_location = {Bratislava},
article_number = {4},
doi = {http://dx.doi.org/10.4149/neo_2018_170519N363},
keywords = {multiple myeloma; lenalidomide; retreatment},
language = {eng},
issn = {0028-2685},
journal = {Neoplasma},
title = {Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients},
volume = {65},
year = {2018}
}
TY - JOUR
ID - 1404546
AU - Štork, Martin - Ševčíková, Sabina - Adam, Zdeněk - Krejčí, Marta - Sandecká, Viera - Král, Zdeněk - Brožová, Lucie - Velichová, Roberta - Pour, Luděk
PY - 2018
TI - Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients
JF - Neoplasma
VL - 65
IS - 4
SP - 585-591
EP - 585-591
PB - Slovenská akademie vied
SN - 00282685
KW - multiple myeloma
KW - lenalidomide
KW - retreatment
N2 - The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.
ER -
ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ and Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients (Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.). \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2018, vol.~65, No~4, p.~585-591. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2018\_{}170519N363.
|
